LT97149A - 2-metil-tieno-benzodiazepino peroralinė vaisto forma - Google Patents

2-metil-tieno-benzodiazepino peroralinė vaisto forma

Info

Publication number
LT97149A
LT97149A LT97-149A LT97149A LT97149A LT 97149 A LT97149 A LT 97149A LT 97149 A LT97149 A LT 97149A LT 97149 A LT97149 A LT 97149A
Authority
LT
Lithuania
Prior art keywords
thieno
oral
methyl
benzodiazepine formulation
benzodiazepine
Prior art date
Application number
LT97-149A
Other languages
English (en)
Other versions
LT4350B (lt
Inventor
George Randall Cochran
Tommy Clifford Morris
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT97149(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT97149A publication Critical patent/LT97149A/lt
Publication of LT4350B publication Critical patent/LT4350B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
LT97-149A 1995-03-24 1997-09-16 2-metil-tieno-benzodiazepino peroralinė vaisto forma LT4350B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24

Publications (2)

Publication Number Publication Date
LT97149A true LT97149A (lt) 1998-01-26
LT4350B LT4350B (lt) 1998-05-25

Family

ID=23624847

Family Applications (1)

Application Number Title Priority Date Filing Date
LT97-149A LT4350B (lt) 1995-03-24 1997-09-16 2-metil-tieno-benzodiazepino peroralinė vaisto forma

Country Status (46)

Country Link
US (4) US5919485A (lt)
EP (2) EP1093815B1 (lt)
JP (1) JPH11502848A (lt)
KR (1) KR100408172B1 (lt)
CN (1) CN1178662C (lt)
AP (1) AP679A (lt)
AR (2) AR002720A1 (lt)
AT (3) ATE284695T1 (lt)
AU (1) AU696601B2 (lt)
BG (1) BG62594B1 (lt)
BR (1) BR9607791A (lt)
CA (1) CA2216372C (lt)
CH (1) CH691217A5 (lt)
CO (1) CO4700474A1 (lt)
CR (1) CR5278A (lt)
CZ (1) CZ296007B6 (lt)
DE (3) DE69615887T2 (lt)
DK (3) DK0733367T3 (lt)
EA (1) EA000938B1 (lt)
EE (1) EE03551B1 (lt)
EG (1) EG24077A (lt)
ES (2) ES2164837T3 (lt)
FI (1) FI973749A (lt)
GB (1) GB2313783B (lt)
HU (1) HU225269B1 (lt)
IL (1) IL117611A (lt)
IS (1) IS1903B (lt)
LT (1) LT4350B (lt)
LU (1) LU90115B1 (lt)
LV (1) LV11983B (lt)
MY (1) MY113440A (lt)
NO (1) NO320388B1 (lt)
NZ (1) NZ306111A (lt)
OA (1) OA10511A (lt)
PE (1) PE44997A1 (lt)
PL (1) PL188316B1 (lt)
PT (2) PT1093815E (lt)
RO (1) RO118370B1 (lt)
SE (1) SE9703206L (lt)
SI (3) SI0733367T1 (lt)
SK (1) SK283745B6 (lt)
TR (1) TR199701018T1 (lt)
TW (1) TW426526B (lt)
UA (1) UA44766C2 (lt)
WO (1) WO1996029995A1 (lt)
ZA (1) ZA962338B (lt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
CA2395774C (en) * 1999-12-28 2009-09-15 Cipla Limited New polymorphic forms of olanzapine
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
AU2002255196A1 (en) * 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7029112B2 (en) 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
CA2785138A1 (en) * 2003-10-07 2005-04-21 Andrx Pharmaceuticals Llc Rapidly disintegrating formulation
EP1684734A2 (en) * 2003-11-18 2006-08-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
BRPI0610780A2 (pt) * 2005-04-22 2016-09-06 Teva Pharma formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete
DK1880001T3 (da) * 2005-05-31 2011-09-12 Iams Company Feline probiotiske lactobacilli
CA2607949C (en) * 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
CN101484141A (zh) * 2006-07-05 2009-07-15 比利姆制药工业和贸易公司 包含抗氧化剂的稳定的奥氮平制剂
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
US8722133B2 (en) * 2008-01-31 2014-05-13 Kyorin Pharmaceutical Co., Ltd. Method for production of orally rapidly disintegrating tablet comprising imidafenacin as active ingredient
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
GB2473981B (en) * 2009-03-25 2012-02-22 Caitin Inc Thermodynamic cycle for cooling a working fluid
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
JP2016531151A (ja) * 2013-09-13 2016-10-06 バイエル ファーマ アクチエンゲゼルシャフト レファメチニブを含有する医薬組成物
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
JP7299166B2 (ja) * 2017-06-02 2023-06-27 ゼリス ファーマシューティカルズ インコーポレイテッド 沈殿抵抗性低分子薬物製剤
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
NO305125B1 (no) * 1992-05-29 1999-04-06 Lilly Industries Ltd Farmas°ytiske forbindelser
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
US6780433B2 (en) 2004-08-24
AU696601B2 (en) 1998-09-17
SI9620041A (sl) 1998-06-30
AT405606B (de) 1999-10-25
EE03551B1 (et) 2001-12-17
DE69615887D1 (de) 2001-11-22
CZ300197A3 (en) 1997-12-17
IS1903B (is) 2003-11-20
DK1093815T3 (da) 2005-04-25
OA10511A (en) 2002-04-24
EP0733367B1 (en) 2001-10-17
SI1093815T1 (en) 2005-06-30
ATE284695T1 (de) 2005-01-15
EP0733367A1 (en) 1996-09-25
NO974363L (no) 1997-11-17
KR100408172B1 (ko) 2004-02-18
SK283745B6 (sk) 2003-12-02
US20050085462A1 (en) 2005-04-21
NO974363D0 (no) 1997-09-22
RO118370B1 (ro) 2003-05-30
CA2216372A1 (en) 1996-10-03
LU90115B1 (fr) 1997-09-10
SE9703206D0 (sv) 1997-09-05
WO1996029995A1 (en) 1996-10-03
EP1093815B1 (en) 2004-12-15
CO4700474A1 (es) 1998-12-29
EA199700260A1 (ru) 1998-02-26
US5919485A (en) 1999-07-06
MX9707186A (es) 1997-11-29
IS4565A (is) 1997-09-22
PL188316B1 (pl) 2005-01-31
TW426526B (en) 2001-03-21
NO320388B1 (no) 2005-11-28
UA44766C2 (uk) 2002-03-15
ZA962338B (en) 1997-09-22
AU5428096A (en) 1996-10-16
LV11983B (en) 1998-07-20
US20010018071A1 (en) 2001-08-30
EA000938B1 (ru) 2000-06-26
PE44997A1 (es) 1997-10-23
BR9607791A (pt) 1998-07-07
KR19980703189A (ko) 1998-10-15
US7229643B2 (en) 2007-06-12
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
PT733367E (pt) 2002-03-28
DE19681287T1 (de) 1998-03-19
CN1178662C (zh) 2004-12-08
ATE206924T1 (de) 2001-11-15
DK109097A (da) 1997-11-12
ES2232379T3 (es) 2005-06-01
LV11983A (lv) 1998-03-20
GB2313783B (en) 1998-11-18
AR002720A1 (es) 1998-04-29
IL117611A0 (en) 1996-07-23
EG24077A (en) 2008-05-11
EP1093815A1 (en) 2001-04-25
HU225269B1 (en) 2006-08-28
JPH11502848A (ja) 1999-03-09
PT1093815E (pt) 2005-03-31
CZ296007B6 (cs) 2005-12-14
LT4350B (lt) 1998-05-25
GB9719817D0 (en) 1997-11-19
DE69615887T2 (de) 2002-04-11
AR001405A1 (es) 1997-10-22
CN1179102A (zh) 1998-04-15
FI973749A0 (fi) 1997-09-22
SI0733367T1 (en) 2002-06-30
MY113440A (en) 2002-02-28
FI973749A (fi) 1997-09-22
NZ306111A (en) 1999-02-25
BG62594B1 (bg) 2000-03-31
EE9700328A (et) 1998-06-15
CR5278A (es) 1996-07-04
CH691217A5 (de) 2001-05-31
CA2216372C (en) 2007-11-20
HUP9800410A3 (en) 2000-01-28
US6190698B1 (en) 2001-02-20
DK0733367T3 (da) 2001-11-26
TR199701018T1 (xx) 1998-01-21
ATA902296A (de) 1999-02-15
ES2164837T3 (es) 2002-03-01
BG101901A (en) 1998-10-30
DE69634053T2 (de) 2005-12-22
IL117611A (en) 2002-05-23
HUP9800410A2 (hu) 1998-07-28
SE9703206L (sv) 1997-09-05
AP679A (en) 1998-09-28
DE69634053D1 (de) 2005-01-20
GB2313783A (en) 1997-12-10
DK173323B1 (da) 2000-07-24
AP9701064A0 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
GB2313783B (en) Oral 2-Methyl-Thieno-Benzodiazepine formulation
EG23826A (en) Pharmaceutical formulations
PL322136A1 (en) Oral compositions
GB9519363D0 (en) Pharmaceutical formulation
AP9600883A0 (en) Pharmaceutical formulations
GB9514842D0 (en) Novel formulation
EP0862431A4 (en) PHARMACEUTICAL PREPARATION
GB9513694D0 (en) Oral compositions
GB9515597D0 (en) Oral compositions
GB9523566D0 (en) Pharmaceutical formulation
HUP9801282A3 (en) Oral compositions
ZA96526B (en) Novel pharmaceutical formulation
HUP9801706A3 (en) Oral compositions
GB9609203D0 (en) Formulations
ZA96392B (en) Pharmaceutical formulations
HU9602732D0 (en) Lanperisone formulation
GB2292886B (en) Oral hygiene formulation
GB9500978D0 (en) Pharmaceutical formulations
GB9510391D0 (en) Oral compositions
GB9513693D0 (en) Oral compositions
GB9508684D0 (en) Novel formulation
GB9509941D0 (en) Formulations
GB9508144D0 (en) Formulations
GB9510349D0 (en) Formulations
GB9525386D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20160322